Our commitment is to improve health through provision of affordable and innovative medicines for better, healthier lives.
About Us
Our Vision
To be a leading Provider of affordable Quality Healthcare solutions in the East African region
Our Mission
To be the preferred supplier of essential medicines by focusing on quality, innovation and customer satisfaction
Our Core Values
Our core values include: Professionalism, Integrity, Teamwork, Transparency and Innovation
Who we are
Kampala Pharmaceutical Industries (KPI) Ltd is one of the leading local pharmaceutical manufacturer in Uganda. Our commitment is to improve health through provision of affordable and innovative medicines for better, healthier lives.
KPI manufactures high quality and affordable essential medicines for communicable and non-communicable diseases as well as food supplements (nutraceuticals) and veterinary products for the domestic and regional markets.
KPI is a member of the Industrial Promotion Services (IPS) group of companies, which is an affiliate of the Aga Khan Fund for Economic Development (AKFED) – an international development agency dedicated to promoting entrepreneurship and building economically sound enterprises in sub-Saharan Africa as well as Central and Southern Asia. AKFED is an affiliate of Aga Khan Development Network (AKDN).
Our History
Kampala Pharmaceutical Industries (KPI) based in Uganda was in 1996 jointly acquired by IPS and a leading Indian drug manufacturer Kopran. While IPS provided management support, Kopran was responsible for technological transfer from India. Over the years, KPI has evolved to become a leading local manufacturer of high quality and affordable medicines, developed by the local people, to address local health issues in East Africa – a truly homegrown solution.
-
KPI bought out
KPI bought out by IPS group and Kopran in a JV
-
Ministry of Health Launched ‘Homapak’
In collaboration with WHO and the Ministry of Health Launched ‘Homapak’ This has been the flagship brand in the Home Based Management of Fever, resulted in an increase in children receiving treatment within 24 hours from 7.3% in 2001 to 55% nationally by the year 2005.
-
Formulation Development Laboratory
Commissioned a Formulation Development Laboratory equipped with stability chambers for accelerated and real time stability studies (First in Uganda)